• Pravastatin and Liver Fibrosis: Insights from the PROSPER Trial

    A recent post-hoc analysis of the PROSPER trial, published in JHEP Reports (2025), highlights the impact of pravastatin in reducing all-cause mortality in elderly patients at risk of liver fibrosis.The…

  • Exploring the Future of Clinical Research in Hodgkin Lymphoma

    In this insightful session, Dr. Wei Xu from Jiangsu Provincial People’s Hospital (The First Affiliated Hospital of Nanjing Medical University) shares her expertise on the foundations and clinical advancements in Hodgkin lymphoma (HL) research. This talk delves into key aspects of HL treatment strategies, research breakthroughs, and what the future holds for clinical applications. Don’t…

  • Five-Year CheckMate 649 Update: Nivolumab Plus Chemo Extends Survival for Chinese Gastric Cancer Patients

    Background The CheckMate 649 trial demonstrated a clinically meaningful improvement in survival when nivolumab was added to chemotherapy in patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma…

  • Dr. Mehdi Karoui’s Contribution to Advancing Colorectal Anastomosis Healing

    A recent study published in Communications Biology explores a promising approach to improving colorectal anastomosis healing using extracellular vesicles (EVs) derived from adipose stromal cells, embedded in a thermoresponsive gel (Pluronic® F127). This innovative strategy aims to reduce post-surgical complications, enhance tissue regeneration, and improve healing outcomes, particularly in patients undergoing radiotherapy​.

  • Real-World Impact of Olaparib in BRCA-Mutant Advanced Pancreatic Cancer

    A new study published in Cancer Medicine by Michele Milella, Giulia Orsi, Mariacristina di Marco, Lisa Salvatore, and colleagues highlights the real-world survival benefits of olaparib in patients with BRCA1/2-mutant metastatic pancreatic cancer (PDAC). Conducted across 23 Italian oncology centers, the analysis revealed that patients exposed to olaparib at any point during their treatment course…

  • Sara Tolaney’s Latest Contribution to HER2-Positive Breast Cancer Treatment

    Dr. Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, continues to lead the research in HER2-positive breast cancer. In her latest study, published in Journal…

  • Mark Robson’s Contribution to BRCA2 Variant Classification in Breast Cancer

    Dr. Mark E. Robson, Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center, continues to lead research in breast cancer genetics. In a January 2025 Nature publication,…

  • Gene Signatures for Personalized Treatment in Colorectal Cancer

    A new study published in Communications Medicine highlights the potential of gene signatures derived from transcriptomic-causal networks to improve patient stratification for targeted therapy in metastatic colorectal cancer (mCRC). By integrating gene interconnectivity into survival analysis, researchers identified distinct gene signatures that predict response to cetuximab or bevacizumab, providing a more personalized approach to treatment.